fashion -WSS

fashion

author：comprehensive 2025-10-02 20:48:23 - browse：5

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Will the FTC rein in IQVIA's health data empire?

WSS

Democrats decry new health bill for going easy on private equity

Democrats decry new health bill for going easy on private equity

Novo Nordisk to expand supply of Wegovy for U.S. patients

A new crop of companies is reshaping the health data economy

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Biden warns of ‘dark winter’ during final presidental debate

hotspot

fashion

explore

Moonlake's readout produced a cash windfall. Risks remain

The lessons of Aduhelm, an Alzheimer's drug that was not to be

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Apple Vision Pro: A first look at health apps on the new VR headset

Dobbs anniversary: the lost opportunity of abortion as health care

What we need to know about Arena Bioworks

State Dept. review finds Biden bears some blame for Afghanistan failures

Device maker Teleflex to acquire urology company for $600M

Peter Hotez and the public health issue of online harassment

What to watch for from Zogenix and Amicus clinical trials

hotspot

SAMSHA loosens regulations on methadone treatment centers

The lessons of Aduhelm, an Alzheimer's drug that was not to be

New Alzheimer's drugs heat up race for early detection blood tests

Vertigo drug brings hope for rare neuron disorder, Niemann

STAT Report: Patient voices and perspectives

FDA drug safety: Singulair case shows systemic surveillance flaws

focus

explore

entertainment

knowledge